

SECO - CEQUA Booth

References for CEQUA® (cyclosporine ophthalmic solution) 0.09%

References:

1. Schechter BA, Urbietta M, Bacharach J, et al. Effect of OTX-101 in patients with dry eye disease at day 14 of treatment: ocular surface endpoint results from the phase 2b/3 clinical trial. *Clin Ophthalmol.* 2022;16:4145-4151.
2. Johnston, J. Effect of OTX-101 0.09% on corneal staining and SANDE scores in patients with dry eye disease uncontrolled on cyclosporine ophthalmic emulsion 0.05%. Abstract presented at American Academy of Optometry 2023; October 12, 2023; New Orleans, LA.
3. Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.
4. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. *Ophthalmology.* 2019;126(9):1230-1237.
5. CEQUA [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022.

© 2024 Sun Ophthalmics, a division of Sun Pharmaceutical Industries, Inc. All rights reserved.
CEQUA is a registered trademark of Sun Pharmaceutical Industries Limited.
PM-US-CQA-1457 01/2024

